Takeda Pharmaceutical Company Limited announced updated data from the Phase 1/2 trial of mobocertinib (TAK-788) orally administered in patients with epidermal growth factor receptor (EGFR) Exon20 insertion mutation-positive (insertion+) metastatic non-small cell lung cancer (mNSCLC) who received prior platinum-based chemotherapy. The results showed mobocertinib continued to demonstrate clinically meaningful benefit after over a year of follow up and will be presented at the virtual 57th American Society of Clinical Oncology (ASCO) Annual Meeting on June 4.
- Read more about Takeda announced Mobocertinib orally administered in patients with epidermal growth factor receptor
- Log in or register to post comments
source https://www.pharmatutor.org/pharma-news/2021/takeda-announced-mobocertinib-orally-administered-in-patients-with-epidermal-growth-factor-receptor
No comments:
Post a Comment